Vaccination: Health agrees that those vaccinated with AstraZeneca under 60 receive the second dose of Pfizer

There is already a decision. The Public Health Commission has agreed on Tuesday that the second dose of mRNA vaccines (Pfizer) be given to people under 60 years of age who received the first dose of the AstraZeneca vaccine, after a Carlos III trial endorsed This option and despite the fact that a study in the United Kingdom showed that combining different vaccines can increase adverse effects.In the meeting that took place this Tuesday afternoon, the autonomous communities and the Ministry of Health have opted for the mixed regimen or heterologous based on observational studies from other countries and clinical trials from Oxford and the Carlos III Health Institute, has reported Health The preliminary results of the 'CombiVacs' clinical trial, launched by the Carlos III Health Institute ( ISCIII), which were released this morning, have shown that a dose of Pfizer's COVID-19 vaccine produces a strong immune response and mild to moderate side effects and n people under 60 years of age who received a single dose of AstraZeneca. The population between 60 and 69 years is out of this strategy, and will also receive their second dose of AstraZeneca. In early April, Health made the decision to vaccinate with the Oxford vaccine only to people over 60 years of age due to the occurrence of "very rare" thrombotic events, especially in younger people, following the example of other European countries such as France or Germany. This restriction caused many under 60 years of age who had already received a dose of AstraZeneca could not receive the required second injection. Those affected are, mainly, essential personnel such as teachers or policemen.